Diagnostic Performance of a Cenomic Classifier for Lung Cancer

摘要

The addition of a new genomic classifier to standard bronchoscopy for the evaluation of lung cancer improved the diagnostic performance regardless of the size, the location, or the stage of the lesion. For patients with a low or intermediate pretest probability for lung cancer, a negative genomic classifier test and bronchoscopy supports imaging surveillance. The study excluded patients who were lifetime nonsmokers or smokers with a history of previously treated lung cancer, limiting the generalizability of its findings. Additional studies are needed to assess the classifier in these patient groups and to validate its performance in clinical practice.